"What if the trial does not meat the endpoints?"
Sorry rivalmoney, your poor grasp of the English language reflects on the value of your postings. "Meat" is a food. "Meet" is to fulfill. Huge difference.
An interesting statement from someone who posts on another board:
"now, I am getting crushed on BCYP, NVIV,WDDD and NLST. Here is a suggestion for all. Whatever I pump up, sell it short."
"I lost 80% of my entire life savings at NLST,"
"Take the bet on my premonition."
I just may take you up on your suggestion. What other stocks are you buying?
ohmtaxi, Interesting that you cannot make the connection the rest of us could. I'll say it slowly so you can understand:
biojax wrote for Seeking Alpha under the pen name "U.S. Biotech Investor". He even posted a few links to his biojax Yahoo! email address in responses to questions about his articles.
usbiovest has a blog titled... You guessed it "U.S. Biotech Investor" which also links to articles on Seeking Alpha as "U.S. Biotech Investor".
Despite your ignorance, sometimes two plus two does equal four.
Wow! Forget Viagra and Cialis - I give you...
"MultiStem for daily use helps you be ready anytime the moment's right." "Before taking MultiStem, ask your doctor if your heart's healthy enough for sexual activity." "To avoid long-term injury, seek immediate medical help for an erection lasting more than four hours."
Actually, they didn't have the leadership. A string of poor decisions by management and the BOD led to the company's downfall. Among other things, their attempt to hide the SAE's of Delparantag, which they obviously knew about in 2012, caused investors to wonder if Brilacidin also had more problems than company was disclosing.
Then Nick alienated pretty much every potential partner and large investor. By the time the BOD gave him his walking papers, the damage had been done. Then they made another mistake promoting their CFO to interim CEO.
The final coupe de grace was administered by Fordham in their handling of the reverse split and equity financing. The Fordham rep who called me lied, saying the shares were oversubscribed when they obviously weren't.
It just goes to show that no matter how good the science is, it also takes good management and a good BOD for a company to become a success. Lesson learned.
The Aspire deal is only potentially $25M. Athersys may or may not sell the shares at their discretion. Think of it like a credit card. You may have x amount of available credit but not necessarily use it.
Where did you come up with the 45 million figure? They will be selling 20M shares plus warrants worth (who knows how much?). The Aspire deal is at their discretion - they may choose to not sell any shares to Aspire, depending on their needs. Neither the Aspire shares nor the warrants count toward market cap at this time.
Spinoff from what? It won't be spun off from NVIV because it's not part of NVIV. If you're going to buy shares of NVIV hoping to get shares of PixarBio I don't recommend you hold your breath.
Besides, why would you be interested in that company? Based on your rants about lawsuits based on Frank's management of NVIV, it doesn't make any sense that you would be interested in investing in his new company. Or are you a masochist?
Then again, Facebook is the premier place to discuss investing .
Have to disagree on that. The stock is already pre-sold to institutions. My dog could broker that if I had one.
I see huge positives in this, especially when taking Japan into account. As others have said, Japan likely won't require large Phase 3 efficacy trials. To me, that means it's possible that decent Phase 2 results could allow sales almost immediately. No wonder Gil took this step now - $20M could be enough to get production and a sales force started there.
Get your facts straight:
ATHX Short Interest
Short Percent of Float: 3.32 %
Short % Increase / Decrease: 11.95
Correct on that one, but:
CYTR Short Interest
Short Percent of Float: 4.02 %
Short % Increase / Decrease: 22.85
Let's see - a larger short percent of float and a larger percentage increase in short interest - yep, CYTR sure is doing better than ATHX, Hyuck, Hyuck....
So what does that prove? Baker Brothers, Citadel, Financial Architects, Knight Capital and Rotella all sold out of your precious CytRx in the last few months and yet you're still pumping it. Do you think anyone here gives a rat's sss about your bashing ATHX and pumping CYTR?
Anyone following your investing advice needs more help than we can give them.
I thought there was only one thing bothering you:
"The only thing that bothers me about ATHX is Gil gets paid 550k a year but owns just less than a million in shares in a company that he started." - nowwhat654 • 6 hours ago
And the answer to your question is no, basher.
The same way they tell thousands of patients in dire need of a possible cure that is currently in clinical trials. SCI victims are far from unique in that respect.
I seriously doubt Athersys will partner for Ischemic stroke. That will be their goldmine.